Name | SB-334867 (free base) |
Synonyms | SB-334867,CID 6604926 SB-334867 (free base) N-(2-METHYL-6-BENZOOXAZOLYL)-N''-1,5-NAPHTHYRIDIN-4-YL UREA 1-(2-Methylbenzo[d]oxazol-5-yl)-3-(1,5-naphthyridin-4-yl)urea 1-(2-methylbenzo[d]oxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea 1-(2-METHYL-1,3-BENZOXAZOL-6-YL)-3-(1,5-NAPHTHYRIDIN-4-YL)UREA N-(2-Methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-ylurea SB334867 |
CAS | 792173-99-0 |
Molecular Formula | C17H13N5O2 |
Molar Mass | 319.32 |
Density | 1.472 |
Boling Point | 450.5±30.0 °C(Predicted) |
Solubility | DMSO: ≥ 49 mg/mL |
Appearance | powder |
Color | white to beige |
pKa | 10.21±0.43(Predicted) |
Storage Condition | room temp |
In vitro study | In CHO-OX1 cells, SB-334867 inhibited orexin-A (10 nM) and orexin-B (100 nM)-induced calcium responses, pKB 7.27 and 7.23, respectively, to UTP (3 microM). The induced calcium response had no effect. |
In vivo study | In male and female rats, sb-334867 (30 mg/kg, I. p.) significantly reduced natural and orexin-A-induced food intake. In rats, 867 (2 mg/kg, I. v.) blocks the effect of antipsychotic drugs on the activity of dopamine neurons. In rats, SB-334867 also inhibits the development of tolerance to morphine analgesia. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.132 ml | 15.658 ml | 31.317 ml |
5 mM | 0.626 ml | 3.132 ml | 6.263 ml |
10 mM | 0.313 ml | 1.566 ml | 3.132 ml |
5 mM | 0.063 ml | 0.313 ml | 0.626 ml |
biological activity | SB-334867 is a selective orexin-1 (OX1) receptor antagonist. SB-334867 is a selective orexin-1 (OX1) receptor antagonist. |
Target | Value |